Yaohai Bio-Pharma has once again been recognized as a leading innovator in the global biopharmaceutical industry. During the 2026 Future Healthcare 100 Conference held on May 21, 2026, the company was selected for both the prestigious “2026 Future Healthcare 100” main ranking and the “Innovative Healthcare Service & Industry Chain Service TOP100” list.
This recognition highlights Yaohai Bio-Pharma’s strong technological innovation, integrated microbial CRDMO capabilities, and expanding international presence. The award reflects the company’s growing contribution to accelerating biologics development and supporting next-generation therapeutic innovation globally.
Recognized for Innovation and Industry Impact
The Future Healthcare 100 ranking is widely regarded as one of the most influential evaluations in the healthcare and life sciences industry. Organized by VB100, Artery Network, and Eggshell Research Institute, the program identifies companies that demonstrate outstanding innovation, growth potential, and industry impact.
Since its launch in 2015, the ranking has recognized thousands of companies across biotechnology, medical technology, healthcare services, and pharmaceutical innovation. Importantly, the “Innovative Healthcare Service & Industry Chain Service TOP100” category focuses on companies that provide critical infrastructure, development, manufacturing, and enabling services across the healthcare ecosystem.
Therefore, Yaohai Bio-Pharma’s continued inclusion reflects its strong position as a trusted microbial CRDMO partner supporting the advancement of innovative biologics and advanced therapeutics.
Strengthening Innovation Through Microbial Expression Technologies
Since its establishment in 2010, Yaohai Bio-Pharma has remained focused on microbial expression systems and advanced biologics manufacturing technologies. Over the years, the company has developed integrated CRDMO platforms covering multiple therapeutic modalities and emerging technology areas.
Today, Yaohai’s core capabilities include:
- Recombinant proteins and peptides
- Nucleic acid therapeutics
- Plasmid DNA
- mRNA and CircRNA technologies
- Nanobodies
- Innovative recombinant vaccines
Among these areas, nucleic acid therapeutics have become a major focus of innovation. Leveraging experience from more than 800 RNA CRO projects, Yaohai has established scalable mRNA production platforms with high capping efficiency and strong RNA integrity.
Furthermore, the company has built advanced LNP formulation and analytical capabilities to improve delivery performance and reduce impurity risks such as double-stranded RNA. These platform technologies enable clients to accelerate development timelines while maintaining high product quality and manufacturing consistency.
At the same time, Yaohai continues to invest heavily in research and innovation. The company has secured multiple invention and utility model patents while expanding its technology infrastructure to support future biologics development.
Delivering End-to-End CRDMO Solutions
Beyond platform innovation, Yaohai Bio-Pharma continues to strengthen its integrated CRDMO service ecosystem. The company provides comprehensive support across the full biologics development lifecycle, from early research through commercial GMP manufacturing.
Its end-to-end capabilities include:
- Strain engineering
- Process development and optimization
- Analytical method development
- GMP manufacturing
- Quality system establishment
- Regulatory support and documentation
In addition, Yaohai operates more than 20,000 square meters of GMP-compliant manufacturing facilities. Its cGMP workshops align with international quality standards and have successfully passed multiple client and regulatory audits.
The company also offers flexible production capacity ranging from 50L to 2000L. As a result, clients can efficiently scale programs from early-stage development to late-stage clinical and commercial manufacturing.
This flexible and integrated service model enables Yaohai to support biotechnology and pharmaceutical companies with faster development timelines, reliable manufacturing, and scalable production strategies.
Expanding Global Collaboration and International Reach
In recent years, Yaohai Bio-Pharma has accelerated its international expansion strategy and strengthened collaboration with global biopharmaceutical partners.
Currently, the company supports more than 300 clients worldwide across diverse therapeutic and technology areas. Moreover, Yaohai continues to enhance its global regulatory understanding and international delivery capabilities to better support multinational development programs.
To strengthen global industry engagement, Yaohai actively participates in major biotechnology and pharmaceutical conferences worldwide. These activities help the company build strategic partnerships, exchange technical expertise, and explore future collaboration opportunities across the global biotech ecosystem.
About Yaohai Bio-Pharma
Yaohai Bio-Pharma is a CRDMO with extensive expertise in microbial expression systems. We focus on recombinant proteins, nucleic acid drugs, nanobodies, plasmid DNA, and innovative vaccines. From R&D to commercial manufacturing, we offer full-lifecycle solutions. Our mission is to build an open, integrated CRO/CDMO/MAH platform that supports global partners from discovery to market.
